Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study - 07/08/19
Doi : 10.1016/j.jaad.2019.04.045
Diamant Thaçi, MD a, ⁎ 
, Lluís Puig, MD, PhD b, Kristian Reich, MD c, Tsen-Fang Tsai, MD d, Stephen Tyring, MD, PhD e, Külli Kingo, MD, PhD f, Michael Ziv, MD, BSc g, Andreas Pinter, MD h, Ronald Vender, MD, FRCPC i, j, Aude Lacombe, PharmD k, Summer Xia, MSc l, Vaishali Bhosekar, MSc m, Isabelle Gilloteau, MSc, MPH k, Adriana Guana, MD n, Andrew Blauvelt, MD, MBA o
, Lluís Puig, MD, PhD b, Kristian Reich, MD c, Tsen-Fang Tsai, MD d, Stephen Tyring, MD, PhD e, Külli Kingo, MD, PhD f, Michael Ziv, MD, BSc g, Andreas Pinter, MD h, Ronald Vender, MD, FRCPC i, j, Aude Lacombe, PharmD k, Summer Xia, MSc l, Vaishali Bhosekar, MSc m, Isabelle Gilloteau, MSc, MPH k, Adriana Guana, MD n, Andrew Blauvelt, MD, MBA o a Research Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany
b Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
c Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
d Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
e University of Texas Health Science Center and Center for Clinical Studies, Houston, Texas
f Dermatology Clinic, Tartu University Hospital, Department of Dermatology, University of Tartu, Tartu, Estonia
g Emek Medical Center, Afula, Israel
h Department of Dermatology, University of Frankfurt, Frankfurt am Main, Germany
i Dermatrials Research Inc, Hamilton, Canada
j Venderm Innovations in Psoriasis, Hamilton, Canada
k Novartis Pharma AG, Basel, Switzerland
l Novartis Beijing Novartis Pharma Co Ltd, Shanghai, China
m Novartis Healthcare Pvt Ltd, Hyderabad, India
n Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
o Oregon Medical Research Center, Portland, Oregon
∗Correspondence to: Diamant Thaçi, MD, Research Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyResearch Institute and Comprehensive Center for Inflammation MedicineUniversity of LuebeckRatzeburger Allee 16023538 Luebeck23538Germany
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 07 August 2019
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Funding sources: Supported by Novartis Pharma AG, Basel, Switzerland. |
|
| Conflicts of interest: Dr Thaci has served as a consultant, advisor, and speaker and has received honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dignity, Dr Reddy, Galapagos, GSK, Janssen, Leo, Lilly, Morphosis, MSD, Novartis, Pfizer, Regeneron, Sanofi, and UCB. Dr Thaci's institute has received research grants from Celgene and Novartis. Dr Puig has served as a consultant and speaker and has received fees and honoraria from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz. Dr Puig's institution has received research funding in relationship with the treatment of psoriasis from AbbVie, Amgen, Janssen, Lilly, Novartis, and Pfizer. Dr Reich has served as advisor or paid speaker and participated in clinical trials sponsored by AbbVie, Affibody, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Covagen, Forward Pharma, Fresenius Medical Care, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Merck Sharp & Dohme Corp, Miltenyi, Novartis, Ocean Pharma, Pfizer, Samsung Bioepis, Sanofi, Takeda, UCB Pharma, Valeant, and Xenoport. Dr Reich has received honoraria for his role as advisor and speaker. For participating in clinical trials, Dr Reich's research site has received patient fees, and Prof Reich has received fees if acting as coordinating investigator. Dr Tsai has served as an investigator or advisor and speaker and has received fees and honoraria from Janssen-Cilag, AbbVie, Pfizer, Leo Pharmaceuticals, Novartis, Celgene, Galderma, Eli-Lilly, Boehringer Ingelheim, GSK, MSD, Allegra, and Tanabe. Dr Tsai's institute has received fees for his role as an investigator. Dr Tyring has served as a principal investigator and his institution has received grant and research funding from Novartis. Dr Kingo has received fees for serving as an investigator in studies sponsored by Celgene, Merck, Mitsubishi Tanabe Pharma, Novartis, Regeneron Pharmaceuticals, and Sandoz. Dr Ziv has served as principal investigator and has received fees from Novartis. Dr Pinter has served as a scientific advisor or clinical study investigator for AbbVie, Allmirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, GSK, Eli-Lilly, Galderma, Hexal, Janssen, Leo Pharma, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Schering-Plough, and UCB pharma. Dr Pinter has served as a paid speaker for AbbVie, Celgene, Eli-Lilly, Janssen, Leo Pharma, Medac, Novartis, and Sanofi Genzyme. Dr Vender has served as an advisory board member, investigator, and on the speakers bureau and has received honoraria from Novartis, AbbVie, Janssen, Lilly, UCB, Amgen, Celgene, Pfizer, and Bauch Health. Ms Lacombe, Ms Xia, and Ms Gilloteau are employees of Novartis. Dr Guana and Ms Bhosekar were employees of Novartis during the conduct of the study and development of the manuscript. Dr Blauvelt has served as a scientific adviser or clinical study investigator for AbbVie, Aclaris, Akros, Allergan, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira Inc, Eli Lilly and Company, Galderma, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Meiji, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Revance, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, and Vidac and as a paid speaker for Eli Lilly and Company, Janssen, Regeneron, and Sanofi Genzyme. |
|
| Previously presented a synopsis of the current research as an ePoster at the 26th European Academy of Dermatology and Venereology Congress, in Geneva, Switzerland, on September 13–17, 2017. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?